1.60Open1.60Pre Close0 Volume23 Open Interest155.00Strike Price0.00Turnover152.00%IV34.52%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry1.60Extrinsic Value100Contract SizeAmericanOptions Type-0.0521Delta0.0016Gamma146.43Leverage Ratio-0.2746Theta-0.0043Rho-7.63Eff Leverage0.0458Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet